{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:07:03Z","timestamp":1789826823451,"version":"4.0.1"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Abemaciclib inhibits renal tubular creatinine secretion and can increase serum creatinine without a true reduction in glomerular filtration rate. Direct real-world comparisons with palbociclib using routinely available laboratory markers are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective study of 56 women with advanced or recurrent hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who initiated palbociclib (n\u2009=\u200929) or abemaciclib (n\u2009=\u200927). Data from January 1, 2018, to June 30, 2026, were extracted. Serum creatinine, creatinine-based estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), and the BUN\/creatinine ratio were evaluated at baseline and Days 14, 28, 42, and 56 using adjusted generalized estimating equations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Drug-by-time interactions were significant for serum creatinine (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.004), eGFR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and the BUN\/creatinine ratio (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.001), but not BUN (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.080). At Day 14, the adjusted between-group difference in change (abemaciclib minus palbociclib) was 0.180\u2005mg\/dL for serum creatinine and \u221211.4\u2005mL\/min\/1.73\u2005m\n                      <jats:sup>2<\/jats:sup>\n                      for eGFR. The BUN\/creatinine ratio difference was not significant at Day 14 but was significant at Days 28 (\u22125.12), 42 (\u22124.11), and 56 (\u22123.83). Sensitivity analyses yielded consistent interaction results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Abemaciclib showed greater and more persistent changes in serum creatinine, creatinine-based eGFR, and the BUN\/creatinine ratio than palbociclib. Serial BUN and BUN\/creatinine ratio measurements may provide supportive context for creatinine elevations but cannot exclude true kidney injury.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261488583","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:17:37Z","timestamp":1789557457000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal comparison of serum creatinine, estimated glomerular filtration rate, and blood urea nitrogen-to-creatinine ratio after initiation of palbociclib or abemaciclib: A single-center retrospective study"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0886-315X","authenticated-orcid":false,"given":"Yuichi","family":"Koizumi","sequence":"first","affiliation":[{"name":"Izumiotsu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Fujitani","sequence":"additional","affiliation":[{"name":"Izumiotsu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nishii","sequence":"additional","affiliation":[{"name":"Izumiotsu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Tsunoda","sequence":"additional","affiliation":[{"name":"Izumiotsu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kamio","sequence":"additional","affiliation":[{"name":"Izumiotsu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Ishiwata","sequence":"additional","affiliation":[{"name":"Kindai University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1296"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00576-5"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/20543581221106246"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.11.033"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111370"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103060"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.5649\/jjphcs.52.544"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_3_13_2","unstructured":"Pfizer Japan Inc. Ibrance tablets 25 mg and 125 mg: Japanese prescribing information (revised December 2024) https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/4291051F1022_2?user=1 (2024 accessed 18 August 2026)."},{"key":"e_1_3_3_14_2","unstructured":"Eli Lilly Japan KK. Verzenio tablets 50 mg 100 mg and 150 mg: Japanese prescribing information (revised December 2021) https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/4291054F1026_1?user=1 (2021 accessed 18 August 2026)."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/73.1.13"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241305417"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz338.104"},{"key":"e_1_3_3_19_2","unstructured":"Pfizer Japan Inc. Ibrance capsules 25 mg and 125 mg; Ibrance tablets 25 mg and 125 mg: Japanese interview form (revised December 2024) https:\/\/pins.japic.or.jp\/pdf\/medical_interview\/IF00002354.pdf (2024 accessed 18 August 2026)."},{"key":"e_1_3_3_20_2","unstructured":"Eli Lilly Japan KK. Launch of Verzenio tablets 50 mg 100 mg and 150 mg (press release in Japanese) https:\/\/mediaroom.lilly.com\/PDFFiles\/2018\/18-57_co.jp.pdf (2018 accessed 18 August 2026)."},{"key":"e_1_3_3_21_2","unstructured":"Eli Lilly Japan KK. Verzenio approved for adjuvant therapy in high-risk hormone receptor-positive HER2-negative breast cancer (press release in Japanese) https:\/\/mediaroom.lilly.com\/PDFFiles\/2021\/21-71_co.jp.pdf (2021 accessed 18 August 2026)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261488583","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261488583","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261488583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:17:50Z","timestamp":1789823870000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261488583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":20,"alternative-id":["10.1177\/10781552261488583"],"URL":"https:\/\/doi.org\/10.1177\/10781552261488583","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"10781552261488583"}}